Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 22, 2022, details the results of the Annual Meeting of Stockholders held by Eledon Pharmaceuticals, Inc. on June 21, 2022. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Global Market under the symbol ELDN.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes were reported in this filing. The primary event was the completion of the Annual Meeting where stockholders voted on director elections and auditor ratification.
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding future guidance, risks, contingencies, or unusual items. It strictly reports the voting outcomes of the Annual Meeting.
Key Facts for Investors
- Director Elections: Stockholders elected Keith A. Katkin and John S. McBride as Class II Directors for a three-year term ending in 2025.
- Voting Results (Directors):
- Keith A. Katkin: 7,330,714 votes For; 765,231 votes Withhold; 2,091,204 Broker Non-Votes.
- John S. McBride: 7,287,222 votes For; 808,723 votes Withhold; 2,091,204 Broker Non-Votes.
- Auditor Ratification: Stockholders ratified the appointment of KMJ Korbin & Company LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Voting Results (Auditor): 10,173,336 votes For; 10,380 votes Against; 3,433 votes Abstain.